Enliven Therapeutics is a late-stage biotech company with $895 million in cash, supporting operations through 2030 and the pivotal Phase 3 ENABLE-2 trial for ELVN-001. This drug targets chronic myeloid leukemia (CML) as a selective ATP-competitive inhibitor, showing promising Phase 1 results with 61% major molecular response at 80 mg daily and a favorable safety profile for chronic use. The company aims for ELVN-001 to become the preferred treatment option in earlier lines of CML therapy, not necessarily replacing all existing tyrosine kinase inhibitors (TKIs). The upcoming ENABLE-2 trial is a key catalyst for the company’s future growth and market positioning.
Baidu announced that its Class A ordinary shares listed on the Hong Kong Stock Exchange will be included in the Shanghai-Hong Kong Stock Connect program starting September 7, 2026. This inclusion allows eligible mainland Chinese investors to directly...
Curaleaf Holdings has opened a new cannabis dispensary in Riverview, Florida, marking its 77th location in the state and 178th across the U.S. This expansion reflects Curaleaf's strategy to grow its presence in Florida's fast-growing medical cannabis...
SpaceX's stock currently trades below its first closing price despite a strong IPO debut, with a consensus analyst target price about 48% higher than the current price. Raymond James analyst Brian Gesuale projects a much more optimistic outlook, sett...
Critical Metals has consolidated 92.5% ownership of the Tanbreez heavy rare earths project and secured a 15-year offtake agreement with REalloys. The company has started a 10,000-meter drilling program to better define its resources. Tanbreez stands ...
Xcel Energy declared a quarterly dividend of $0.5925 per share, continuing its streak of annual dividend increases aligned with its 4%-6% raise policy. The company operates as a regulated utility, providing predictable cash flows supported by state-a...
